Everest Organics completes USFDA inspection at Hyderabad manufacturing facility

08 Mar 2017 Evaluate

Everest Organics has successfully completed USFDA inspection at its flagship API manufacturing facility in Hyderabad. The company has vision to enter into very niche areas of high margin API products as well as development of new products through its R & D, thereby increasing both top line as well as substantial improvement in bottom line in forthcoming years.

Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.

Everest Organics Share Price

461.95 -13.45 (-2.83%)
18-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.35
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 913.85
Lupin 2118.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×